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Pseudomonas aeruginosa infection is a predominant cause of morbidity and mortality
in patients with cystic fibrosis infection and with a compromised immune system.
Emergence of bacterial resistance renders existing antibiotics inefficient, and therefore
discovery of new antimicrobial agents is highly warranted. In recent years, numerous
studies have demonstrated that antimicrobial peptides (AMPs) constitute potent
agents against a range of pathogenic bacteria. However, AMPs possess a number
of drawbacks such as susceptibility to proteolytic degradation with ensuing low
bioavailability. To circumvent these undesired properties of AMPs unnatural amino acids
or altered backbones have been incorporated to provide stable peptidomimetics with
retained antibacterial activity. Here, we report on antimicrobial α-peptide/β-peptoid
lysine-based peptidomimetics that exhibit high potency against clinical drug-resistant
P. aeruginosa strains obtained from cystic fibrosis patients. These clinical strains
possess phoQ and/or pmrB mutations that confer high resistance to colistin, the
last-resort antibiotic for treatment of infections caused by P. aeruginosa. The lead
peptidomimetic LBP-2 demonstrated a 12-fold improved anti-pseudomonal activity as
compared to colistin sulfate as well as favorable killing kinetics, similar antibiofilm activity,
and moderate cytotoxicity.
Keywords: peptidomimetic, Pseudomonas aeruginosa, antimicrobial, cystic fibrosis, resistance
INTRODUCTION
Pseudomonas aeruginosa is a nosocomial pathogen that causes severe chronic and acute infections,
leading to high morbidity and mortality, especially among immunocompromised patients (Lyczak
et al., 2000). For several decades, this bacterium has been the most prevalent respiratory pathogen
in patients with cystic fibrosis (CF) (Høiby et al., 2010). Once P. aeruginosa has colonized the
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respiratory tract mucosal epithelium it is almost impossible to
eradicate, resulting in a chronic lung infection (Banerjee and
Stableforth, 2000). The ability of P. aeruginosa to form robust
biofilms renders antibiotic treatment inefficient while promoting
resistance development (Drenkard, 2003). Continuous intensive
antibiotic treatment and high tolerance of biofilms have resulted
in the emergence of multidrug-resistant (MDR) P. aeruginosa
strains (Johansen et al., 2008; Høiby et al., 2010; Mulcahy et al.,
2014). Colistin constitutes the last-resort antibiotic against these
MDR infections, and hence development of resistance to colistin
among CF patients is particularly worrying (Moskowitz et al.,
2012). Lipopolysaccharide (LPS) that constitutes the major part
of the Gram-negative outer membrane interacts with colistin
through electrostatic bonds between its anionic phosphate groups
and the protonated amino groups of the highly cationic cyclic
lipopeptide (Storm et al., 1977). Colistin resistance and induced
colistin tolerance is associated with reduction of the bacterial
outer-membrane negative charge conferred by modification of
lipid A and the core oligosaccharide with 4-amino-L-arabinose
(L-Ara4N) residues, thereby diminishing interactions between
colistin and LPS (Moskowitz et al., 2004; Pamp et al., 2008;
Lee and Ko, 2014).
In 2016, FDA approved a new combination of two commonly
used drugs for treatment of infections caused by P. aeruginosa,
namely ceftolozane and tazobactam. However, it has not been
well studied in cystic fibrosis patients with an MDR P. aeruginosa
infection (Ang et al., 2016; Haidar et al., 2017; Shortridge et al.,
2017). No new classes of antibiotics against Gram-negative
bacteria have been introduced for clinical use in recent years
(Butler et al., 2017; Fernandes and Martens, 2017), and hence the
discovery of alternative potent antimicrobial compounds against
Gram-negative pathogens is of crucial importance. This implies
that development of new approaches for successful treatment of
P. aeruginosa infections will alleviate a major health issue.
Antimicrobial peptides (AMPs) play a crucial role in the innate
host defense as the frontline endogenous defense molecules that
prevent establishment of infections caused by invasive pathogens
(Haney et al., 2017; Molchanova et al., 2017a). Within the last
decade, AMPs have been demonstrated to possess potency against
various susceptible and resistant P. aeruginosa strains e.g., several
synthetic AMPs were reported to exert antibacterial activity with
minimum inhibitory concentrations (MICs) of 1 µg/mL (Lim
et al., 2006; Joshi et al., 2010; Shin, 2014; Monteiro et al., 2015).
Notably, cecropin displayed MIC and minimum bactericidal
concentration (MBC) values of 0.75 and 1.5 µg/mL, respectively
(Abou-Zied et al., 2015). In addition, it has been reported that
certain AMPs successfully inhibit bacterial biofilm development,
and therefore may be used in combination with commonly used
antibiotics to prevent biofilm formation as well to eradicate
established biofilms (de la Fuente-Nunez and Hancock, 2015;
Andrea et al., 2018).
Though AMPs are considered as potential leads for novel
antibacterial agents, they generally suffer from several
shortcomings, e.g., poor bioavailability due to susceptibility
to proteolytic degradation and their often unfavorable hemolytic
and cytotoxic properties conferring a narrow therapeutic window
(Rotem and Mor, 2009). Incorporation of peptoid residues (i.e.,
N-alkylated glycine residues) leads to enhanced proteolytic
stability while allowing for the introduction of side chains similar
to those present in natural α-amino acids as well as a vast number
of variations only limited by the availability of suitably protected
primary amines (Zuckermann and Kodadek, 2009). In a previous
study, an α-peptide/α-peptoid hybrid was found to exhibit
potent activity against P. aeruginosa demonstrating prevention
of biofilm formation (Jahnsen et al., 2013). Additionally, recent
structure-activity relationship studies revealed that a subclass of
α-peptide/β-peptoid hybrids (e.g., lysine-based peptidomimetic
1 = LBP-1) display broad-spectrum activity against Gram-
positive and Gram-negative bacteria (Molchanova et al., 2017b),
and that LBP-2 was demonstrated to possess high potency against
P. aeruginosa (Klodzinska et al., 2018). In the present study, we
have designed a few next-generation analogs based on LBP-2
and investigated the activity of this series of compounds against
P. aeruginosa strains including several resistant strains obtained
from CF patients.
MATERIALS AND METHODS
Chemicals and General Procedures for
Compound Characterization
Starting materials and solvents were purchased from commercial
suppliers (Iris Biotech, Sigma-Aldrich, and Merck) and were
used without further purification. H-Rink-Amide ChemMatrix
resin (loading 0.52 mmol/g, 0.05 mmol) was purchased from
PCAS BioMatrix Inc., QC, Canada. Preparative HPLC was
performed by using a Phenomenex Luna C18 (2) column
(250 mm × 21.2 mm; 5 µm particle size) on a Shimadzu
Prominence system using an aqueous MeCN gradient with 0.1%
TFA added (eluent A: 5:95 MeCN − H2O with 0.1% TFA added;
eluent B: 95:5 MeCN − H2O with 0.1% TFA added). Analytical
UHPLC was performed by using a Phenomenex Luna C18 (2)
HST column (100 mm × 3.0 mm; 2.5 µm particle size) on a
Shimadzu Prominence and Shimadzu Nexera system by using
the above eluents A and B. All tested compounds had a purity
of at least 95%. HRMS spectra were obtained by using a Bruker
MicrOTOF-Q II Quadrupole MS detector.
Manual Synthesis of Peptidomimetics
Peptidomimetics were prepared manually in teflon vessels
(10 mL; fitted with a polypropylene filter) using dimeric
α-peptide/β-peptoid building blocks as previously described
(Bonke et al., 2008). Dimeric building blocks were synthesized as
previously reported (Bonke et al., 2008). In brief, 5.0 equiv Fmoc-
protected dimeric building block, 5.0 equiv PyBOP (benzotriazol-
1-yl-oxytripyrrolidinophosphonium hexafluorophosphate) and
10.0 equiv DIPEA (N,N-diisopropylethylamine) were mixed and
added to the resin, which then was shaken at room temperature
for at least 2 h. Fmoc deprotection was performed with 20%
piperidine in N,N-dimethylformamide (DMF, 2 × 10 min, each
time with 5 mL under shaking at room temperature). Each step
was followed by washing with DMF, MeOH, and CH2Cl2 (each
for 3 × 3 min, each time with 5 mL under shaking at room
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temperature). Capping was performed with the mixture Ac2O–
DIPEA–(N-methyl-2-pyrrolidone) 1:2:3 (5 mL for 10 min under
shaking at room temperature) after the loading of the first dimeric
building block. Cleavage of the peptidomimetics from the resin
and simultaneous side-chain deprotection were carried out by
2 × 1 h treatments with the mixture TFA–TIS–H2O (95:2.5:2.5).
The crude product was purified by preparative HPLC. For elution
of peptidomimetics, a linear gradient of 10% → 60% B during
10 min was used with UV detection at λ = 220 nm. The
appropriate fractions were concentrated in vacuo and lyophilized;
compound identity was verified by HRMS, and purity (>95%)
was determined by analytical UHPLC.
Strain Description
The non-mucoid wild-type P. aeruginosa strain PAO1, and its
isogenic mucoid variant Alg+PAOmucA22 (PDO300) were used
as control strains in this study (Hengzhuang et al., 2011). Clinical
isolates of P. aeruginosa PA1016, PA1603 PA77685, PA44638,
and PA41782 were collected from the sputum of CF patients.
PA1016 and PA1603 have both phoQ and pmrB mutations (Miller
et al., 2011; Moskowitz et al., 2012). PA77685 and PA44638 have
pmrB mutation. PA41782 has phoQ mutation (Miller et al., 2011;
Moskowitz et al., 2012). All selected clinical strains with phoQ
and/or pmrB mutations showed high resistance to colistin.
Determination of Minimal Inhibitory
Concentrations
Pseudomonas aeruginosa strain PAO1 and clinical isolates
were obtained from Department of Clinical Microbiology,
University Hospital of Copenhagen, Denmark. Minimal
inhibitory concentrations (MICs) were determined by the
broth microdilution method according to CLSI protocol (CLSI,
2012). Each bacterial strain was diluted to a concentration of
5 × 105 CFU/mL in Luria-Bertani (LB) medium (Statens Serum
Institut, Denmark), and was added to a twofold serial dilution
of each peptidomimetic in 96-well plates (Nunc Internationals,
Rochester, NY, United States). After incubation upon shaking
for 18–20 h at 37◦C, the MICs were determined as the lowest
concentration showing no visible growth. Experiments were
performed in triplicates on two different days.
Time-Kill Kinetics
Planktonic P. aeruginosa (0.1 mL with 106 CFU/mL) was added
into microtiter wells with LB medium (Hengzhuang et al.,
2011). Different concentrations of antimicrobials (in a volume of
0.1 mL) were mixed into different wells, shaken and incubated at
37◦C for 0, 1, 2, 4, 8, 12, 24, and 48 h. Samples (0.1 mL) from wells
were cultured overnight on LB plates (Staten Serum Institute,
Copenhagen, Denmark) and CFU were counted. Experiments
were performed in two technical replicates. Killing curves of
antimicrobials on planktonic cells were plotted.
Biofilm Eradication Assay
Biofilm assays were performed by a modified Calgary biofilm
device method (Hengzhuang et al., 2011). Isolates were grown
overnight in Luria-Bertani (LB) medium. After dilution of this
culture to ∼107 CFU/mL, 0.10 mL was transferred to all wells
(except for that with the negative control) of a flat-bottom
96-well microtiter plate (catalog no. 269787; Nalgene Nunc
International, Rochester, NY, United States). The minimal growth
medium (ABTG medium) for biofilm cultivation consisted of
1 mM MgCl2, 0.1 mM CaCl2, 15.1 mM (NH4)2SO4, 33.7 mM
Na2HPO4, 22 mM KH2PO4, 51 mM NaCl, 0.01 mM FeCl3,
2.5 µg/mL thiamin, and 0.5% glucose. The ABTG medium was
refreshed every 24 h in wells for biofilm cultivation. Bacterial
biofilms were formed by immersing the pegs of a modified
polystyrene microtiter lid (catalog no. 445497; Nunc TSP system)
into the biofilm growth plate, followed by incubation at 37◦C for
3 days without shaking. The crystal violet staining method was
employed to estimate the biofilm formation on the pegs. Peg lids
were rinsed three times in sterile water, placed onto flat-bottom
microtiter plates containing antimicrobials in twofold dilutions
in 0.12 mL of ABTG medium per well (antimicrobial challenge
plate), and cultivated for 20 h at 37◦C. After antimicrobial
incubation, peg lids were again rinsed 3 times in sterile water and
placed into antibiotic-free LB in a flat-bottom microtiter plate
(biofilm recovery plate) after sonication. To transfer biofilms
from pegs to wells, the sonication was performed at 4◦C for 2–
5 min using Bransonic 220 (80 W, 42 KHz, Branson Co., Shelton,
CT, United States). The optical density at 650 nm (OD650) was
measured in a microtiter plate reader (Kinetic Microplate Reader,
manufactured by Molecular Devices, Novo Biolab, Denmark)
before and after incubation at 37◦C for 8–12 h. Determination
of the minimum biofilm eradication concentration (MBEC) was
performed in triplicates on two different days and detected after
24 h recovery, and defined as the concentration of drug that
resulted in an increase of OD650< 0.05.
In vitro Hemolytic Activity
The lysis of human red blood cells (hRBCs) was measured as
previously described (Molchanova et al., 2017b). In brief, hRBCs
from a freshly drawn type 0+ blood sample were washed with
PBS buffer (pH 7.2, 10 mM Tris, 150 mM NaCl), and then
centrifuged once at 700 × g for 8 min and twice at 1000 × g for
8 min each time. Twofold serial dilutions of the peptidomimetics
in PBS buffer were added to each well in a round-bottom 96-
well plate (Nunc, Thermo Scientific, NY, United States) with a
volume of 20 µL in each well. A 1% (v/v) hRBC suspension
(80 µL in PBS buffer) was added to reach a total volume of
100 µL in each well. The plate was incubated (37◦C) for 1 h,
and then the cells were pelleted by centrifugation at 1000 × g for
10 min. The supernatant (60 µL) was transferred to a new 96-well
plate, and the hemoglobin content was detected by measuring
the OD (with a VersaMax Microplate Reader from Molecular
Devices, LLC, San Jose, CA, United States) at 414 nm. The OD
of samples incubated with melittin (400 µg/mL) defined 100%
hemolysis, while the OD of samples incubated with PBS buffer
defined 0% hemolysis. Tests were performed twice in triplicates
on two different days.
Cell Culturing
Two different cell lines, HepG2 and NIH 3T3 (both from
ATCC, Manassas, VA, United States) were cultured to ∼90%
confluence after 21–25 h of growth under standard conditions
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(5% CO2/95% O2 at 37◦C): Seeding densities for HepG2 and
NIH 3T3 were 6.97× 104 and 6.67 × 104 cells/cm2, respectively.
HepG2 cells were cultured in Eagle’s Minimal Essential Medium
supplemented with 10% (v/v) fetal bovine serum (FBS), 1%
(v/v) of non-essential amino acid (NEAA) mixture, and 1 mM
sodium pyruvate. NIH 3T3 cells were cultured in Dulbecco’s
Modified Eagle’s Medium supplemented with 10% (v/v) newborn
calf serum (NCS) (Gibco, Paisley, United Kingdom). All
culture media were supplemented with penicillin (100 IU/mL),
streptomycin (100 µg/mL), and L-glutamine (2 mM). All cell
media and supplements were obtained from Sigma-Aldrich
(St. Louis, MO, United States), except serum (Gibco, Paisley,
United Kingdom). The 96-well plates were from Corning Costar
(Sigma-Aldrich, Brøndby, Denmark).
Cell Viability Assay
Cell viability assessment was performed on cell monolayers
grown to ∼90% confluence in 96-well plates by using the
MTS/PMS assay as previously described (Molchanova et al.,
2017b). Briefly, the adhered cells were washed with 37◦C Hanks’
balanced salt solution (HBSS from Sigma-Aldrich, St. Louis,
MO, United States) containing 10 mM HEPES (AppliChem,
Darmstadt, Germany), pH 7.4, and exposed for 1 h at 37◦C to
100 µL of peptidomimetic dissolved in the medium also used
for culturing of each cell line (at concentrations in the range 0–
1000 µM). Then the cells were washed twice with 37◦C HBSS
containing 10 mM HEPES (pH 7.4), and then 100 µL of an
MTS/PMS solution, consisting of 240 µg/mL MTS (Promega,
Madison, WI, United States) and 2.4 mg/mL PMS (Sigma-
Aldrich, Buchs, Switzerland) in HBSS, were added to the cells,
which then were incubated for 1 h at 37◦C with horizontal
shaking (50 rpm) protected from light. A POLARstar OPTIMA
plate reader (BMG Labtech, Offenburg, Germany) was used to
measure the absorbance at 492 nm. The relative viability was
calculated by using 0.2% (w/v) sodium dodecyl sulfate (SDS) as
the positive control, while cells exposed to medium without test
compound were used as the negative control. Data were obtained
in two independent biological replicates performed on separate
passages of cells and on separate days with a total number of
six replicates.
RESULTS AND DISCUSSION
Three 16-mer peptidomimetics consisting of alternating cationic
lysine and β-peptoid phenylalanine-like hydrophobic residues
(Figure 1) were obtained by assembly of dimeric building
blocks on a Rink amide resin, followed by cleavage from
the linker and final purification by preparative HPLC (Bonke
et al., 2008). Within this series (i.e., LBP-2, LBP-3, and LBP-
4; Figure 1) the length of the β-peptoid side chains was
gradually increased thereby conferring increased hydrophobicity
and flexibility. Previously, we have reported a SAR study based on
peptidomimetic LBP-1 that showed a general moderate potency
against Gram-negative bacteria. Thus, the influence of the length
of the cationic side chains was investigated in a series of analogs
where ornithine and 2,4-diaminobutyric acid were incorporated
instead of lysine (Molchanova et al., 2017b). Although this
led to slightly improved activity against Gram-positive bacteria,
no improvement in potency was observed toward Gram-
negative pathogens including P. aeruginosa. As a next step, we
introduced an extra carbon into the hydrophobic side chains
to yield the 16-mer peptidomimetic LBP-2 (Klodzinska et al.,
2018). Interestingly, LBP-2 demonstrated high potency against
planktonic P. aeruginosa, while the corresponding 12-mer analog
displayed more than eightfold lower activity. Therefore, in the
present study two novel peptidomimetics LBP-3 and LBP-4 with
elongated hydrophobic side chains were designed to further
investigate the correlation between hydrophobicity and anti-
pseudomonal activity.
Currently, colistin is considered to be the last-resort
antibiotic against MDR P. aeruginosa infections, however, colistin
resistance occurring through a number of various mutations has
become critically prevalent (Dosselmann et al., 2017). Therefore,
colistin was included as a control when analogs LBP-2, LBP-3,
and LBP-4 were tested against a panel of P. aeruginosa strains
(Table 1), also comprising colistin-resistant clinical isolates and
displaying phoQ and pmrB mutations, obtained from CF patients.
PhoPQ and PmrAB systems play important roles in the resistance
of P. aeruginosa to polymyxin and other cationic antimicrobial
peptides (Gutu et al., 2013; Lee et al., 2016). PhoPQ and PmrAB
systems regulate the degree of palmitoylation of lipid A in
P. aeruginosa. In the present study, P. aeruginosa strains with
phoQ and pmrB mutations that are involved in resistance to
cationic AMPs and colistin were included in the investigation of
the killing effect of the series of peptidomimetics.
Analogs LBP-2 and LBP-3 exhibited similar antibacterial
activities (Table 1), while LBP-4 displayed a two- to fourfold
decreased potency. However, this apparent loss of activity most
likely arises from an unfavorable interaction with the medium
resulting in partial precipitation due to its high hydrophobicity,
which can be correlated to the high percentage of acetonitrile
required at peak elution in reversed-phase UHPLC (Table 2;
Jahnsen et al., 2015). All analogs displayed similar or slightly
lowered activity against colistin-resistant clinical isolates as
compared to that seen toward the wild-type strains. Remarkably,
the peptidomimetics were more active against colistin-resistant
strains PA1016 and PA1603 with both pmrB and phoQ mutations,
while exhibiting four- to eightfold decreased activity against
strains possessing either pmrB (PA77685, PA44638) or phoQ
(PA41782) mutation.
Anti-biofilm potency was detected against a mature biofilm (3-
days-old) grown on peg lids immersed into media in a microtiter
plate. Though none of the analogs exhibited improved anti-
biofilm activity as compared to that of colistin, it is noticeable
that the least hydrophobic analog was the only peptidomimetic
that displayed potency similar to that of colistin with respect to
biofilm eradication (Table 1).
In order to assess the potential therapeutic utility of the
peptidomimetics (e.g., in animal studies), their hemolytic
properties as well as effects on cell viability of HepG2 and
NIH 3T3 cell lines were determined (Table 2). Expectedly,
hydrophobicity was found to be closely correlated to the
hemolytic activity of the compounds. Nevertheless, it was
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FIGURE 1 | Structures of the peptidomimetics.
TABLE 1 | Antimicrobial activity of peptidomimetics against Pseudomonas aeruginosa, including colistin-resistant clinical isolates from CF patients; and minimal biofilm
eradication concentrations (MBECs) against a 3-day-old biofilm.
Compound MIC (µg/mL)∗ MBEC∗∗ (µg/mL)
PAO1 PDO300 PA1016 PA1603 PA77685 PA44638 PA41782
LBP-2 2 4 4 4 8–16 32 16–32 64
LBP-3 4 4 2 2 8 8–16 16 128
LBP-4 16 16 16 4 16 16 32–64 256
colistin 0.5 0.5 256 >512 32–64 32–64 256 64
∗P. aeruginosa strains: PAO1 – non-mucoid wild type; PDO300 – isogenic mucoid variant of PAO1. Clinical isolates of P. aeruginosa collected from the sputum of CF
patients: PA1016 and PA1603 have both phoQ and pmrB mutations; PA77685 and PA44638 have pmrB mutation; PA41782 has phoQ mutation. ∗∗MBEC was tested
for PAO1 and PDO300 strains for colistin, LBP-2, LBP-3, and LBP-4. The results of MBEC for all tested compounds were similar for both biofilms formed by PAO1 and
PDO300 strains. Clinical strains showed poor biofilm formation ability on polystyrene surface system, and therefore these were not used for MBEC testing.
TABLE 2 | Cell viability (IC50), hemolytic activity and hydrophobicity of second-generation peptidomimetics.
Compound IC50 (µg/mL); confidence intervals are stated in brackets HD10 (µM)∗ % B∗∗
HepG2 NIH 3T3
LBP-2 63.1 (59.7–67.0) 181.0 (153.0–217.0) >300 37.8
LBP-3 24.3 (20.8– 8.3) 65.3 (60.4–70.6) <4.7 (81%) 43.8
LBP-4 33.7 (31.2–37.9) 104.0 (95.4–113.0) <4.7 (100%) 49.3
∗HD10 designates the concentration of peptidomimetic that results in hemolysis of 10% of human red blood cells; values are also stated in brackets as percent of
hemolysis at 4.7 µM. ∗∗Hydrophobicity is indicated by the percentage of acetonitrile (%B) at the peak elution time on analytical reversed-phase HPLC.
somewhat surprising that incorporation of one additional carbon
in the hydrophobic side chains resulted in such a dramatic
increase in hemolytic properties (i.e., ∼100-fold lower HD10
value). The overall cytotoxicity profiles also reflected this, but to
a lower degree, since the IC50 values for analog LBP-3 were less
than threefold lower than those of LBP-2, whereas the relatively
higher values for LBP-4 can be ascribed to limited solubility in the
medium (seen as a turbidity).
Since compound LBP-2 displayed high potency and the most
favorable cell selectivity it was selected for further investigation.
As MIC values mainly assess antibiotic efficacy, but do not
provide details on the dynamics of the drug-bacteria interaction,
time-kill kinetics of LBP-2 and colistin were determined (during
48 h) against the colistin-resistant strain PA1603, isolated from a
CF patient (Figure 2).
PhoPQ and PmrAB system loss-of-function mutations can
contribute to high-level colistin resistance in clinical strains of
P. aeruginosa (Miller et al., 2011; Moskowitz et al., 2012). The
disruption of chromosomal phoQ in the presence of an intact
phoP allele stimulates 4-amino-L-arabinose addition to lipid
A and induces transcription from the promoter of the pmrH
(arnB) operon. The expression of mutant pmrB alleles induces
transcription from the promoter of the arnB operon and further
stimulates addition of 4-amino-L-arabinose to lipid A. Such lipid
A modifications are known to play a key role in colistin resistance
(Miller et al., 2011; Gutu et al., 2013).
As seen from the time-kill curves (Figure 2), peptidomimetic
LBP-2 at the highest concentration (256 µg/mL) gave rise to
complete killing within 1 h with no regrowth, whereas colistin
failed to exhibit complete killing at the same concentration with
ensuing regrowth after 4 h. In addition, regrowth occurs only
after a lag period of 4–8 h when treating with 16 or 64 µg/mL of
peptidomimetic, whereas regrowth upon treatment with colistin
at these concentrations appears to occur immediately after
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FIGURE 2 | Time-kill kinetics of peptidomimetic LBP-2 (A) and colistin (B) against a clinical resistant strain (PA1603; with phoQ and pmrAB mutations) isolated from
a CF lung. Error bars indicate ± SD.
reaching the maximal initial killing. This indicates that adaption
to LBP-2 might involve a different resistance mechanism as
compared to that for colistin, which in turn infers that LBP-2
and colistin act via different killing mechanisms. Previous studies
on a related subclass of α-peptide/β-peptoid hybrids indicated a
mode of action involving a general membrane-disruptive process
(Hein-Kristensen et al., 2011).
In order to investigate the stability of peptidomimetic
LBP-2 toward proteolytic degradation, it was exposed to the
versatile degradation enzyme pronase (a commercial protease
mixture isolated from Streptomyces griseus) for 48 h. As
seen from Supplementary Figure S1 compound LBP-2 was
not degraded by pronase, and therefore it is considered
resistant to proteolysis over a period of 24 h. This is in
accordance with a previous study where all-L peptides were
found to be prone to enzymatic degradation, while the peptoid
analogs were essentially unaffected (Miller et al., 1994). Other
peptidomimetics such as α/β-peptides, α-peptoids, β-peptoids
and peptide-peptoid hybrids have likewise been demonstrated to
possess similar stability toward proteolysis (Schmitt et al., 2007;
Jahnsen et al., 2012).
Several studies have shown that cationic peptides and
peptidomimetics display high bactericidal activity against
planktonic P. aeruginosa cells, as well as an ability to prevent
biofilm formation. To date, LL-37 is the most studied peptide
capable of inhibiting P. aeruginosa biofilm formation at a
concentration of 0.5 µg/mL, which is 16-fold below its MIC
value against planktonic P. aeruginosa (Overhage et al., 2008),
but also the peptides IDR-1018 (at 0.8 µg/mL), DJK-5 and
DJK-6 (at 10 µg/mL) exhibit activity against P. aeruginosa
biofilms (De Brucker et al., 2014; de la Fuente-Nunez et al., 2015;
Mansour et al., 2015). Other examples of anti-biofilm compounds
comprise three α-helical peptides that were able to reduce biofilm
formation at sub-inhibitory concentrations, while two of them
showed biofilm-reducing activity equal to that of tobramycin
(Pompilio et al., 2012). In addition, several peptidomimetics
have also been found to have similar anti-biofilm properties,
e.g., the group of Barron showed that a peptoid and its lipidated
shorter analog were less effective in eradicating established
biofilms than in preventing their formation. Thus, these
compounds were capable of killing planktonic cells that could
otherwise contribute to establishment of biofilm (Kapoor
et al., 2011). Another study on lipopeptides demonstrated
the same trend, however, only the least hydrophobic cationic
lipopeptides were able to penetrate deep into the innermost
layers of the biofilm matrix, hence exhibiting high killing efficacy
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(Sanchez-Gomez et al., 2015). In another study, the peptide-
peptoid hybrid HDM-4 exhibited strong anti-biofilm activity
at sub-MIC level (Jahnsen et al., 2013). Noticeably, most of
the mentioned peptides and peptidomimetics display biofilm-
inhibitory activity rather than an ability to eradicate established
biofilms, which is the case only for a few compounds.
CONCLUSION
Our data for the LBP series support the trend that, albeit the
peptidomimetics display high activity against planktonic cells,
they lack efficacy toward established biofilms. Additionally, in
accordance with previous observations, a correlation between
relatively low hydrophobicity and improved anti-biofilm activity
was demonstrated. Compound LBP-2 possessed the most
promising cytotoxicity profile and exhibited rapid bactericidal
effect against a colistin-resistant P. aeruginosa strain. Moreover,
peptidomimetic LBP-2 exhibited potent activity against a colistin-
resistant P. aeruginosa strain with phoQ and pmrB mutations as
compared to that of colistin (i.e., 4 vs. >512 µg/mL). Therefore,
the mechanisms of action of compound LBP-2 and colistin
appear to be different, inferring that peptidomimetic LBP-2 may
not bind or binds in a different way to LPS in the outer membrane
of P. aeruginosa. In addition, colistin and LBP-2 exerted similar
potency in anti-biofilm inhibition (64 µg/mL). Compound LBP-
2 displayed a faster and more efficient killing kinetics after just
1 h at 256 µg/mL, while killing was slower and regrowth was
observed already after 4 h for bacteria exposed to colistin at the
same concentration. Peptidomimetic LBP-2 proved to be stable
toward enzymatic degradation, but exhibited some cytotoxicity.
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